DrugPatentWatch Database Preview
EMERPHED Drug Patent Profile
Email this page to a colleague
When do Emerphed patents expire, and what generic alternatives are available?
Emerphed is a drug marketed by Nexus Pharms and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in EMERPHED is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emerphed
A generic version of EMERPHED was approved as ephedrine sulfate by AKORN on March 1st, 2017.
Summary for EMERPHED
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EMERPHED |
| What excipients (inactive ingredients) are in EMERPHED? | EMERPHED excipients list |
| DailyMed Link: | EMERPHED at DailyMed |
Pharmacology for EMERPHED
| Drug Class | alpha-Adrenergic Agonist beta-Adrenergic Agonist Norepinephrine Releasing Agent |
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
| Physiological Effect | Increased Norepinephrine Activity |
Anatomical Therapeutic Chemical (ATC) Classes for EMERPHED
US Patents and Regulatory Information for EMERPHED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus Pharms | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EMERPHED
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| ⤷ Free Forever Trial | ||
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EMERPHED
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1110543 | 08C0004 | France | ⤷ Free Forever Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
| 1110543 | SPC/GB08/005 | United Kingdom | ⤷ Free Forever Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
